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We have previously shown that peripheral blood lymphocytes (PBL) from individuals carrying a germline TP53 mutation show a
dramatically reduced apoptotic response to radiation. As part of a study of this phenomenon, we also investigated apoptotic
response in a series of breast cancer patients lacking TP53 mutations and in a control group of individuals without cancer. There was a
significant reduction in mean apoptotic response with increasing age in all groups. These findings are consistent with a number of
studies in rodents, which have demonstrated a reduction in DNA damage-induced apoptosis with increasing age. In addition, after
adjusting for age, breast cancer patients showed significantly reduced apoptotic responses compared with normal controls
(P¼ 0.002). The odds ratio for breast cancer in women with an apoptotic response of o35%, compared with women with a
response of 449%, was 6.42 (95% CI 1.68–24.6). The data further support the hypothesis that a reduction in apoptotic response to
DNA damage with increasing age may play a significant role in the age-related increase in cancer.
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A number of recent studies have shown a reduced apoptotic
response to DNA damage with increasing age in rodents. For
example, Polyak et al (1997) observed a reduced apoptotic
response of lymphocytes to 5 Gy radiation in mice with increasing
age. Suh et al (2002) found a reduced apoptotic response in rat
liver cells exposed to methyl methane-sulphonate. Both of these
papers discuss the possibility that the sharp rise in cancer
incidence (and perhaps other diseases) with age may be partly
related to a systemic failure of apoptosis.
We have previously published results concerning apoptotic
response to gamma radiation in peripheral blood lymphocytes
(PBL) from carriers of germline TP53 mutations. Cells from such
individuals have a defective apoptotic response when subjected to
gamma radiation (Camplejohn et al, 1995, 2000; Camplejohn et al,
2001). The reduction in apoptotic response is such that there is
essentially no overlap in the response distributions in TP53
mutation carriers and normal controls (12 vs 46% mean response,
Po0.0001 in the two groups in Camplejohn et al (2000)). This
reduction in apoptotic response exactly mirrors that seen in
thymocytes from heterozygous TP53 knockout mice (Clarke et al,
1993; Lowe et al, 1993). We now report results on almost 500
individuals including a group of female breast cancer patients
lacking a TP53 mutation, a group of unaffected individuals from
cancer-prone families and a normal control group. These data have
allowed us to investigate changes in apoptotic response with
increasing age and to compare response in the group of breast
cancer patients with controls.
MATERIALS AND METHODS
Subjects
For the purposes of the analyses reported in this paper, individuals
with a germline TP53 mutation were excluded. To achieve this, all
individuals with a clinical history consistent with Li– Fraumeni
syndrome/Li– Fraumeni-like syndrome (LFS/LFL), and individuals
with a very low apoptotic response (o32%) were screened using
sequencing and/or the FASAY, a functional assay of TP53 status
(Duddy et al, 2000). Samples were obtained from three main
groups of individuals: (i) Normal controls (n¼ 75), who were
either patients or members of hospital staff, had never had cancer
and whose families had no unusual history of the disease. (ii)
Breast cancer patients who attended either the Genetics clinic at
the Royal Marsden Hospital or the Breast Cancer Unit at Guy’s
Hospital. Owing to the referral patterns for these clinincs, this
group was biased towards patients with a family history of breast
cancer. Of the 243 female breast cancer patients, 72 germline
BRCA1 and five BRCA2 mutations were detected. (iii) Members of
cancer-prone families (n¼ 80), who themselves had not had
cancer. This group was heterogeneous, consisting of members of
BRCA1, BRCA2 and other cancer predisposing mutation families,
some of whom carried the mutation in question and some of whom
did not. In addition, included in this group were individuals from
Received 26 April 2002; revised 19 September 2002; accepted 21
November 2002
*Correspondence: Dr RS Camplejohn;
E-mail: r.camplejohn@cancer.org.uk
British Journal of Cancer (2003) 88, 487 – 490
& 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00
www.bjcancer.com
C
li
n
ic
a
l
families with multiple cases of cancer for whom the genetic basis of
this susceptibility was unknown. Finally, the apoptotic assay was
performed on a small number of patients with cancers other than
breast cancer (n¼ 39) and on four male breast cancer patients
(Table 2). All patient samples were taken with written informed
consent in accord with local ethical committee approval.
Apoptotic assay
Separation and culture of PBL Whole blood (25 ml) was collected
in preservative-free heparinised tubes and taken as rapidly as
possible to the laboratory for separation of mononuclear cells.
After removal of plasma, PBL were separated by centrifugation on
Histopaque (Sigma, Dorset, England), washed and resuspended in
10 ml RPMI 1640 medium (Gibco, Paisley, Scotland) containing
10% serum plus antibiotics. Cell concentrations were determined
using a Casy Counter (Schaerfe System, Reutlingen, Germany) and
the concentration adjusted by addition of medium so as to achieve
a concentration of 5 105 PBL ml1. A 10 ml measure of this
suspension was added to a series of Falcon T25 tissue culture flasks
(Becton Dickinson, Oxford, England) and the cells were cultured
for 70 h and either irradiated or mock-treated. Following a further
24 h, culture cells were split into three aliquots and fixed in 70%
ethanol.
Irradiation procedure Irradiation was carried out using a
Gammacell 1000 Elite (Nordion International Inc., Ontario,
Canada) containing a caesium 137 source and with a dose rate
of 858 cGy min1. Cells were subjected to a dose of 4 Gy except in
the dose –response experiment outlined below. A total of 4 Gy was
chosen as a dose of radiation, which induces a maximum apoptotic
response in all groups of individuals (Figure 1). To produce the
data in Figure 1, 50 ml of blood was obtained from a series of
normal individuals, breast cancer patients lacking a germline TP53
mutation and, for comparison, a group of TP53 mutation carriers.
PBL were separated and treated as described above except that
aliquots of cells were exposed to radiation doses between 0 and
6 Gy.
Analytical flow cytometry After removal of ethanol, 2 106 cell
aliquots were subjected to treatment with 0.1 M Hcl at 371C for
12 min to extract low molecular weight DNA. After washes, cells
were stained for DNA content by addition of propidium iodide (PI-
Sigma) at a final concentration of 50 mg ml1 and RNAse (Sigma) at
a final concentration of 250 mg ml1 in a volume of 1 ml. Cells were
stained for a minimum of 30 min prior to measurement of red
fluorescence (PI), forward and 901 light scatter on a FACSCalibur
flow cytometer (Becton Dickinson, Oxford, England). At least
10 000 cells per sample were scanned and data stored in list mode
prior to analysis using CellQuest software. Doublet discrimination
using pulse area/width analysis on the PI signal was used to
remove cell clumps from the analysis.
Measurement of apoptosis Measurement of the extent of apop-
tosis was performed by assessment of cells appearing in a sub-G1
peak on DNA profiles. The apoptotic response to radiation was
defined as the increase in apoptosis seen when comparing the
irradiated with the unirradiated sample (% apoptosis after 4 Gy%
apoptosis after 0 Gy). This flow cytometric method has been
validated in many publications and by comparison in our
laboratory with a number of other techniques including electron
microscopic counting of apoptotic cells and cell sorting of
apoptotic cells (Camplejohn et al, 1995).
Statistical analysis
The apoptotic response measure used was found to be roughly
normally distributed, and analyses were therefore performed on
apoptotic response untransformed. The effect of age was first
examined by linear regression. The effect of cancer status on
apoptotic response was assessed by multiple regression. To adjust
for age as a potential confounder, we included age as a covariate as
o30, 30–39, 40– 49, 50– 59 or 60+ years. We estimated the odds
ratios for cancer risk at different levels of apoptotic response using
logistic regression. Apoptotic response was categorised as o35%,
35–40%, 40– 49% and 449%, which defined four roughly equally
frequent categories in the data set. Age (using the same five
categories defined above) was again included as a covariate.
Repeated measurements on the same individual were used to
estimate the proportion of the variance because of individual
variation, using analysis of variance. Analyses were performed
using S-plus.
RESULTS
The apoptotic response of PBL to a range of doses of ionising
radiation is shown in Figure 1, for a subset of breast cancer
patients, controls and, for comparison, a group of TP53 mutation
carriers. This small dose –response experiment demonstrates that
cells from all three groups have a maximal apoptotic response at
around 4 Gy.
There was a significant reduction in apoptotic response to 4 Gy
irradiation in all groups of individuals with increasing age
(Table 1). Among the breast cancer patients, there was a marked
decline with age (P trend¼ 0.002), with the mean apoptotic
response declining from 48.9% for cases aged below 30 years to
37.1% for cases aged 60 and over. A decline with age was also seen
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Figure 1 The above graph plots mean radiation-induced apoptosis as a
percentage of total PBL in a control group (solid line, n¼ 6), a group of
general breast cancer patients (dashed line, n¼ 5) and, for comparison, a
group of LFS/LFL TP53 mutation carriers (thick dashed line, n¼ 6). Error
bars show the s.e. between each data measurement.
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for unaffected individuals with a family history (P¼ 0.0001), and a
similar pattern was observed for the control group (P¼ 0.08),
although in this case the effect was less definite because of the
small number of controls over the age of 40. Age-adjusted
apoptotic response for male controls was lower than that for
females (mean difference 7.06, P¼ 0.01).
The mean apoptotic response at 4 Gy for each category is shown
in Table 2. After adjusting for age, breast cancer cases had a
significantly lower mean apoptotic response than unselected
normal controls (adjusted mean difference 5.74, P¼ 0.005). Among
the breast cancer cases, the age-adjusted mean score was slightly
lower for BRCA1/2 carriers than noncarriers (mean difference 3.77,
P¼ 0.014). After excluding known BRCA1/2 carriers, the difference
in mean score between cases and controls was reduced (mean
difference 3.61, P¼ 0.11). Interestingly, the mean apoptotic
response for male breast cancer patients was lower than that for
female breast cancer patients, but this result was based on only
four patients.
The estimated odds ratios for breast cancer by level of apoptotic
response, after adjusting for age by logistic regression, are shown
in Table 3. The most marked effect is for apoptotic response
o35%, which is associated with an estimated odds ratio of 6.42
(95% CI 1.68–24.6) compared with individuals with a score of
449% (P trend¼ 0.005).
DISCUSSION
Mean apoptotic response reduced with increasing age in all groups
(Table 1). This was seen clearly in the breast cancer cases and in
unaffected women with a family history of cancer, but was also
apparent in the unrelated control group, although the number of
older controls was small. Polyak et al (1997) observed a reduced
apoptotic response of lymphocytes to 5 Gy radiation in mice as
they aged, and suggested that similar data on humans would be of
interest. Suh et al (2002) found a reduced apoptotic response in rat
liver cells exposed to methyl methane-sulphonate. Both of these
papers discuss the possibility that the sharp rise in cancer
incidence (and perhaps other diseases) with age may be partly
related to a systemic failure of apoptosis. The age distribution of
breast cancer incidence in humans is usually attributed to the fact
that several rate-limiting somatic mutational events are required to
generate a malignant tumour (Armitage et al, 1961), with a slowing
down of the carcinogenic process at the menopause because of the
lower mitotic rate in postmenopausal women. However, in a recent
study (Peto et al, 2000), an alternative model was proposed in
which a woman’s breast cancer incidence rises sharply to a high
constant rate at a genetically determined age. Systemic failure of
DNA repair processes, including apoptosis, might be one of the
mechanisms behind such a model.
This possibility is supported by the finding that the group of 243
female breast cancer patients without a known TP53 mutation
showed an unexpected and statistically significant (P¼ 0.002)
reduction in apoptotic response to DNA damage compared to
controls. Many of the genes involved in the apoptotic pathway
have been documented, and polymorphisms in these or related
genes may explain the observed variability in apoptotic response.
Perhaps reflecting this, there is some evidence of BRCA1 and
BRCA2 mutation carriers having a lower apoptotic response than
other breast cancer patients. Alternatively, it is possible that the
decreased apoptotic response may be caused by the onset of
cancer, or the treatment of it, rather than preceding it. Prior
therapy is a potential problem with this study in that 134 of the 243
female breast cancer patients had radiotherapy or some type of
systemic therapy at various times prior to the apoptotic assay
being performed. However, apoptotic response for the group of
patients receiving no such therapy (mean apoptotic re-
sponse¼ 40711% s.d.) was virtually identical to that for the
whole group (39.0711.0% s.d.) and thus it does not seem likely
that therapy had a significant effect on apoptotic response. The
general idea that apoptotic response to DNA damage and
susceptibility to cancer are linked is supported by work in mice.
Splenocytes from C57BL/6 mice show a large and rapid apoptotic
response to 1 Gy radiation, in comparison with splenocytes from
DBA/2 mice, in which the response is slower and reduced in extent
(Wallace et al, 2001). Radiation-induced malignancy is greater in
DBA/2 as compared with C57BL/6 mice. Nevertheless, with regard
to the link between apoptotic response and breast cancer in
humans, a larger case–control study based on incidence cases
without systemic treatment and with better age matching of
controls would be needed to resolve any uncertainty.
The finding of a statistically significant reduction in apoptotic
response with age in humans supports the hypothesis set out by
Table 1 Summary of the effect of age on apoptotic response to 4 Gy
irradiation
Category of individual (mean % apoptotic
response (number of individuals))
Age (years)
Breast
carcinoma
Unaffected with family
history of cancer Controls
o30 48.9 (6) 47.9 (7) 52.4 (19)
30–39 42.2 (61) 44.7 (18) 48.2 (20)
40–49 37.8 (69) 40.6 (18) 43.7 (3)
50–59 37.6 (76) 36.1 (14) 44.3 (5)
X60 37.1 (31) 27.9 (7) 43.7 (1)
Table 2 Summary of apoptotic assay results for groups defined by gender and disease status
Category of
individual
Gender (number
of individuals)
Mean apoptotic response to 4 Gy
irradiation (% 7s.d.)
Significance of difference
with controls*
Control Female (48) 49.1710.2 F
Male (27) 43.1712.0 F
Breast carcinoma Female (243) 39.0711.0 P=0.002
BRCA1/2+ve (77) 37.4711.3
BRCA1/2ve (166) 39.8710.8
Male (4) 33.275.16 NA
Sarcoma Female (8) 37.3717.0 P=0.008
Male (15) 49.378.5 NS
Other carcinoma Female (11) 32.779.5 P=0.007
Male (5) 44.7710.9 NS
*Significance of difference in mean response compared with controls, after adjusting for age.
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Polyak et al (1997) and Suh et al (2002), based on rodent data, that
such a reduction may play an important role in age-associated
disease processes. In relation to cancer specifically, this hypothesis
is further supported by the reduced apoptotic response seen in
breast cancer patients vs normal controls.
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